Navigation Links
Drug increases hemoglobin in Myelodysplastic Syndrome

Patients with Bone marrow disorder Myelodysplastic Syndrome (MDS), treated with 500 mcg of Aranesp (Darbepoetin alfa) for every three weeks found to improve the hemoglobin content in 70% of patients. //The new drug Aranesp is manufactured by Amgen Biotech, which conducted a Phase II trial with 200 low-risk MDS patients who were administered with 500 mcg of Aranesp every three weeks. MDS is a pre-leukemia stage in which the bone marrow does not produce the required blood cells. MDS is associated with abnormal blood counts resulting in anemia (low red blood cell count), Neutropenia (low white blood cell count) and Thrombocytopenia (low blood platelet count).

Professor Janice Gabrilove, Medical Oncologist, Mount Sinai School of Medicine, New York said that, “During the course of their disease, the majority of MDS patients develop clinically significant anemia, which can lead to fatigue and the need for red blood cell transfusions currently, there are no recombinant erythropoietic products approved for the treatment of anemia in MDS patients."

The Phase II trial was conducted for 13 weeks and their erythroid response was evaluated by measuring the hemoglobin, 70 percent of patients had an erythroid response, with 49 percent classified as major response , 67% of patients achieved the target hemoglobin level of 11 g/dL. 19% in the erythropoietin-naive group had at least one transfusion during the 13-week observation period. In the group previously treated with an erythropoietic agent (n= 59), 44 percent experienced an erythroid response, with 24 percent classified as major. Forty-five percent of patients achieved the target hemoglobin level of 11 g/dL, and 29 percent had at least one transfusion.

Source: Eurekalert.


'"/>




Page: 1

Related medicine news :

1. Human gene number increases
2. Stress response increases suicide risk
3. Sleep apnoea increases post-operative risks
4. Vaginosis increases risk of miscarriage
5. Serotonin increases stroke risk
6. Depression increases heart attacks
7. Excess vitamin A increases fracture risk
8. High vitamin A increases risk of hip fractures
9. Less sleep increases mortality rates
10. Smoking during pregnancy increases risk of cleft palate
11. Obesity increases health costs
Post Your Comments:
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...hospital, which enables care for people in North S... board, will now offer the cancer// drug Herceptin...osts for this medicine estimated at ?47,000, will ...ufferers who are not from Wales. With effect from...
...tness to a yearly exodus phenomenon of nearly 15,0...king their land for raking// in the moolah elsewhe...O, warning against serious implications on the cou...tary Francisco Duque, the problem is really grave ...
...Glenda has increased the spread of the potentially...halitis// (MVE), in Western Australian regions, Ki... Kimberley has spread the virus that causes Murray...Glenda along with the more recent cyclone Hubert h...
...shed in the issue of International Journal of Canc...the risk of cervical cancer in women//. According...th the International Collaboration of Epidemiologi...that current smokers were 60 percent more likely t...
Other Medicine News:
(Date:10/10/2008)...Mass., Oct. 10 /- Boston Sc... the schedule of the Company,s major,events and pr...oundation,s,(CRF) twentieth annual Transcatheter C...ium, which runs from October 12 to 17 in Washingto...ide range of safety and,efficacy data on its TAXUS...
(Date:10/9/2008)... Clinical Results Expected in November 2008, BOTH... Pharma, Inc.,(Amex: DDD ) announced today the co...third of its three pivotal trials to evaluate the ...extended-release (ER) ibuprofen for,the over-the-c... top-line,results from this pivotal trial in Novem...
(Date:10/8/2008)...gs May Someday Inform Treatments for Spinal Cord, ...ewswire-USNewswire/ -- A protein that enables,nerv... role in controlling,the developing nervous system...nections to form among nerve cells may provide a b...er injuries to their nervous system,including spi...
(Date:10/8/2008)...ndings Confirm Potency of Poly-ICR as Vaccine Adju... Nventa Biopharmaceuticals,Corporation (TSX: NVN) ...dies using its proprietary Toll-like Receptor 3 ag...rld Vaccine Congress 2008 in Lyon, France.,Study r...e adjuvant,targeting the Toll-like Receptor 3 (TLR...
Breaking Medicine Technology:Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 3Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 4Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 6SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5Michel Nakache Returns to Euro RSCG Life as Worldwide Managing Partner 18395 1Michel Nakache Returns to Euro RSCG Life as Worldwide Managing Partner 18395 2NorthPoint Domain and NYU Vascular Associates Partner to Develop New Generation of Care Delivery Informatics Instruments 5098 1NorthPoint Domain and NYU Vascular Associates Partner to Develop New Generation of Care Delivery Informatics Instruments 5098 2NorthPoint Domain and NYU Vascular Associates Partner to Develop New Generation of Care Delivery Informatics Instruments 5098 3Kidney disease worsens in a fourth of African Americans despite therapy for hypertension 18389 1Kidney disease worsens in a fourth of African Americans despite therapy for hypertension 18389 2PLC Systems to Host First Quarter Conference Call on May 15 2008 5094 1PLC Systems to Host First Quarter Conference Call on May 15 2008 5094 2
...2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) a...t Loma Linda University Medical Center,National J...ity,showing that one of the Company,s metalloporph...tion of healthy normal cells in mice,with prostate...tudy,also showed that the compound did not interfe...
...Vascular Disruption,Capabilities of Azixa(TM), TAR.../ --,EpiCept Corporation reported today that studi...TM), a compound licensed by the,Company to Myriad ...condary brain tumors, were presented at the annual...earch (AACR) in Los Angeles,California. , The fin...
Other Medicine Technology:Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential as a,Protector of Healthy Normal Cells from Cancer Radiation Therapy 2Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential as a,Protector of Healthy Normal Cells from Cancer Radiation Therapy 3Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR 2Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR 3Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR 4Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR 5
...es To Allow Full Visualization Of The Diamond Blad...lished Double Footplate Construction Insures Preci...ension Settings Of 0.5mm, 0.55mm, 0.6mm, Including... Snub Nose Diamond Blade Is Ideal For Making The P...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification.
2.5V Halogen source, fiber-optic delivery, 3X magnification, pocket-sized.
All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheostat for fine control of il
Medicine Products: